Mild Cognitive ImpairmentMExeProMCINCT07334392
Impact of a Multicomponent Exercise Program on Cognitive and Functional Outcomes in Patients With Mild Cognitive Impairment
A study testing Innovative therapeutic exercise program, Therapeutic exercise program and Flyer in people with Mild Cognitive Impairment and Walking, run by University of Patras at 1 site in Greece.
Trial summary
The goal of this randomised clinical trial is to investigate the effectiveness of an innovative therapeutic exercise program emphasizing in dual-task exercises in people with amnestic Mild Cognitive Impairment. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Mild Cognitive Impairment, Walking, Balance
- What is being tested?
- Innovative therapeutic exercise program, Therapeutic exercise program and Flyer
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteGreece
- Study dates
- 1 Dec 2025to 30 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- individuals > 50 years old
- people with confirmed cognitive impairment, as evidenced by values within normal limits on the Montreal Cognitive Assessment test (MOCA ) >20
- stable medication in the last month
- independent walking
Who cannot join
- people with dementia
- people suffering from chronic mental illness (e.g. schizophrenia, bipolar disorder)
- people suffering from a neurological disorder or injuries (e.g. multiple sclerosis, Parkinson's, traumatic brain injury)
- people with clinical depression (as determined by the Neuropsychiatric Inventory (NPI) assessment and medical diagnosis)
- people who have had recent surgery
- people with insufficient knowledge of the Greek language
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sofia Lampropoulou contact
Greece1 site, 1 recruiting
- Recruiting
Department of Physiotherapy, University of Patras
Pátrai
Sofia Lampropoulou, lampropoulou@upatras.gr
Evdokia Biliis, billis@upatras.gr
About this study
Official title: Effectiveness of an Innovative Therapeutic Exercise Program on Physical and Cognitive Function in Mild Cognitive Impairment Due to Alzheimer's Disease
The goal of this randomised clinical trial is to investigate the effectiveness of an innovative therapeutic exercise program emphasizing in dual-task exercises in people with amnestic Mild Cognitive Impairment. The main questions it aims to answer are:
Does the innovative therapeutic exercise program improve gait and balance? Does the innovative therapeutic exercise program improve cognition?
Read more
Researchers will compare the innovative therapeutic exercise program emphasizing in dual-task exercises to a therapeutic exercise program without emphasizing in dual-task exercises and to a control group (given instruction about the benefits of exercise).
Participants will:
- Perform the exercise program twice a week for three months.
- Will be assessed before and after the intervention.
- Will record The Borg Scale of Perceived Exertion every second week to monitor and assess the progression of exercise intensity.
- Conditions
- Mild Cognitive Impairment, Walking, Balance, Cognition
- Being tested
- Innovative therapeutic exercise program, Therapeutic exercise program, Flyer
- Keywords
- kinetic and kinematic, balance, global cognition, executive function, attention, mci, multicomponent program, exercise, dual tasking
- Medical subject headings
- Cognitive Dysfunction, Neurocognitive Disorders, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Innovative therapeutic exercise programOther
Aerobic, strengthening and balance exercises combined with cognitive training -name: Experimental group 1 (EXP1)
Therapeutic exercise programOther
Aerobic, strengthening and balance exercises without cognitive training- name: Experimental group 2 (EXP2)
FlyerOther
The control group will receive only educational material in the form of a flyer, outlining the importance and potential benefits of physical activity, along with general lifestyle recommendations, without participating in the structured exercise intervention- name: Control group (CG)
| Study group | Role | What they receive |
|---|---|---|
| Innovative therapeutic exercise program emphasizing in dual tasking | Experimental | Participants will perform aerobic exercises, strengthening exercises and balance exercises combined with cognitive exercises at the same time for 60- 90 minutes/ twice a week/ three months. Receives: Other: Innovative therapeutic exercise program |
| Therapeutic exercise program | Active comparator | Participants will perform aerobic exercises, strengthening exercises and balance exercises for 60- 90 minutes/ twice a week/ three months. Receives: Other: Therapeutic exercise program |
| Control group | Active comparator | The control group will be provided with educational material in the form of a flyer outlining the health benefits of exercise and general lifestyle recommendations. Receives: Other: Flyer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Kinematic and kinetic gait assessment
Participants will be instructed to walk at their self-selected, comfortable walking pace. Gait performance will be assessed under four task conditions: single-task walking, dual-task walking, single-task obstacle crossing, and dual-task obstacle crossing. These conditions are designed to evaluate participants' walking ability and adaptability under both simple and cognitively demanding circumstances.
Duration: ≈ 40 minutes
Measured: baseline, post- intervention (12 weeks)
Functional Gait Assessment (FGA)
The Functional Gait Assessment is a clinical tool used to evaluate postural stability during various walking tasks. The assessment includes 10 standardized walking tasks, each addressing a distinct aspect of gait and balance. Performance on each task is rated on a 4-point ordinal scale (0-3), where higher scores indicate better functional performance. The total score ranges from 0 to 30, with a higher total score representing normal gait and balance, and a lower score indicating gait instability or impaired functional mobility.
Test duration: ≈ 10-15 minutes
Measured: baseline, post- intervention (12 weeks)
mini Balance Evaluation Systems Test (mini-BESTest)
The Mini-BESTest is a clinical balance assessment tool designed to evaluate dynamic balance control and identify the specific balance systems affected in individuals with balance disorders. It is a shortened version of the original Balance Evaluation Systems Test (BESTest).
It comprises 14 items, each scored on a 3-point ordinal scale (0-2), with a maximum total score of 28 points.
The assessment includes four subscales, each representing a specific component of balance control:
Anticipatory Postural Adjustments - maximum score: 6 points Reactive Postural Control - maximum score: 6 points Sensory Orientation - maximum score: 6 points Dynamic Gait - maximum score: 10 points Higher scores indicate better balance performance, while lower scores reflect greater balance impairment.
Test duration: ≈ 15minutes
Measured: baseline, post- intervention (12 weeks)
Montreal Cognitive Assessment (MoCA)
The MoCA assesses global cognitive function across multiple domains. It includes 12 brief tasks, grouped into 7 cognitive domains:
Total possible score: 30 points. Each task contributes a set number of points according to its complexity. If the individual has ≤ 12 years of education, 1 additional point is added to the total score to account for educational effects.
Higher score indicates better global cognition while lower scores indicate impairment Administration time: ≈ 10-15 minutes
Measured: baseline, post- intervention (12 weeks)
Cognitive Telephone Screening Instrument (COGTEL)
The test consists of six subtests, each targeting a specific cognitive domain:
- Prospective Memory:(Score range: 0-2 points)
- Verbal Short-Term Memory: (Score range: 0-8 points)
- Verbal Long-Term Memory : (Score range: 0-8 points)
- Working Memory (Backward Digit Span): (Score range: 0-12 points)
- Verbal Fluency: (Score = number of correct words produced)
- Inductive Reasoning: (Score range: 0-8 points)
Each subtest yields an individual score, which are combined into a total composite score using a weighted formula reflecting the relative contribution of each domain to overall cognition:
Total COGTEL score =(7.2 × Prospective Memory) + (1.0 × Verbal Short-Term Memory) + (0.9 × Verbal Long-Term Memory) + (0.8 × Working Memory) + (0.2 × Verbal Fluency) + (1.7 × Inductive Reasoning) Higher score indicates better cognitive performance while lower scores indicate impairment Administration time: ≈ 10-15 minutes
Measured: baseline, post- intervention (12 weeks)
Stroop Test
The Stroop test is a sensitive index of executive function and attention. During the task, the participant is required to name the color of the ink in which a word is printed rather than read the word itself.
Total number of correct responses within a set time limit (60 seconds), and number of errors (including self-corrections and uncorrected errors) are calculated.
Higher scores indicate better executive control, while lower or negative scores suggest difficulty inhibiting automatic responses.
Administration time: ≈5-10 minutes
Measured: baseline, post- intervention (12 weeks)
Secondary outcomes (12)
Lipid profile
Plasma samples will be collected from the participants and will be analyzed using standardized biochemical and immunoassay techniques. The samples will be analyzed to assess changes associated with the intervention.
Parameters Measured: total cholesterol Blood sample collection: ≈ 5 minutes
Measured: baseline, post- intervention (12 weeks)
Hand grip strength test
The Hand Grip Strength Test is a widely used assessment of upper limb muscle strength, particularly of the forearm and hand flexor muscles. The test measures maximum isometric grip force, which reflects not only upper limb strength but also overall muscle function.The participant holds the dynamometer and squeezes as hard as possible for 3-5 seconds. Three trials are performed per hand, with 30-60 seconds of rest between trials. The mean score of the three trials (kg) are reported for each hand. Results are compared to age- and sex-specific normative data.
Administration time: ≈ 3- 5 minutes
Measured: baseline, post- intervention (12 weeks)
30 Second Sit to Stand Test
The 30-Second Sit-to-Stand Test (also known as the 30-Second Chair Stand Test) is a simple, reliable measure of lower limb strength, endurance, and functional mobility. Participant sits in the middle of the chair, back straight, feet flat on the floor, shoulder-width apart, and arms crossed over the chest. On the command "Go," the participant stands up fully and sits down as many times as possible within 30 seconds. The participant must fully extend the knees and hips when standing and sit back fully each time. Partial stands do not count. The assessor counts the number of completed stands within 30 seconds. More repetitions indicate better lower-body strength and endurance. Scores below age- and sex-specific norms indicate reduced lower-body strength and increased fall risk.
Administration time: ≈2-3 minutes
Measured: baseline, post- intervention (12 weeks)
Falls Efficacy Scale - International (FES-I)
The Falls Efficacy Scale - International (FES-I) is a standardized self-report questionnaire designed to assess an individual's concern or fear of falling during various everyday activities. The original FES-I includes 16 items, each describing a common daily activity. Participants rate their concern about falling while performing each activity, regardless of whether they actually do it. Each item is rated on a 4-point Likert scale: 1 (Not at all concerned)-4 (Very concerned). Total Score: 16-64 points. Higher scores indicate greater concern about falling and lower confidence in performing activities safely.
Administration time: ≈10 minutes
Measured: baseline, post- intervention (12 weeks)
6 Minute Walk Test (6MWT)
The 6-Minute Walk Test is a widely used test to assess functional exercise capacity. It measures the distance an individual can walk on a flat, hard surface in six minutes. The participant is instructed to walk as far as possible for 6 minutes, at their own pace, without running. They may slow down, stop, and rest if necessary, but should resume walking as soon as they are able. Standardized encouragements are given at each minute (e.g., "You are doing well. Keep up the good work"). The total distance walked in meters is recorded at the end of 6 minutes.
Total administration time: ≈ 10-15 minutes (including preparation and recovery)
Measured: baseline, post- intervention (12 weeks)
Timed Up and Go test (TUG)
The TUG test measures functional mobility, specifically the time it takes for a person to rise from a chair, walk a short distance, turn, return, and sit down again. The participant begins seated in a standard armchair (seat height ≈ 45 cm).
On the command "Go," the participant must: Stand up from the chair,Walk 3 meters (10 feet) at a comfortable and safe pace,Turn around,Walk back to the chair, and sit down again.The timer starts when the participant's back leaves the chair and stops when they sit down again. Lower times indicate better functional mobility. Higher times suggest mobility impairment and increased fall risk.
Test duration: ≈ 3-5 minutes
Measured: baseline, post- intervention (12 weeks)
Short Physical Performance Battery- (SPPB)
The Short Physical Performance Battery (SPPB) is a standardized test used to assess lower extremity function, mobility, and physical performance in older adults. The SPPB consists of three main components, each assessing a different aspect of lower-body performance: Standing Balance Test, Gait Speed Test, Chair Stand Test. Each of the three components is scored on a 0-4 scale, based on performance time or ability. Component scores (0-4) are summed to give a total score (0-12). Higher scores indicate better functional performance, while lower scores reflect greater functional limitation.
Test duration: ≈ 10minutes
Measured: baseline, post- intervention (12 weeks)
Exercise Adherence Rating Scale (EARS)
The EARS is a self-report questionnaire designed to measure how well individuals adhere to prescribed exercise programs. The EARS comprises three sections (A, B, and C) though the primary adherence measurement is in Section B.
Section A: Captures qualitative information about the prescribed exercise (type, frequency) as given by the healthcare provider.
Section B: Contains 6 items that assess exercise adherence behavior. Section C: Contains 10 items related to reasons for non-adherence (barriers and facilitators).
The 6 adherence items of Section B are each scored on a 5-point Likert scale: 0 = "strongly agree" to 4 = "strongly disagree".
The sum of the 6 items yields a raw adherence score ranging from 0 to 24. A higher score indicates better adherence to the prescribed exercise protocol. Total administration time (including instructions): ≈5 minutes
Measured: end of 4 weeks of intervention, end of 8 weeks of intervention, end of intervention (12 weeks)
Word Finding Questionnaire - Brief Version (WoFi-Brief)
The WoFi-Brief is a shortened version of the WoFi (Word Finding) questionnaire, which is used to assess difficulties in word retrieval. The WoFi-Brief consists of 16 items and is designed to efficiently evaluate an individual's word-finding ability. Each item is rated on a Likert-type scale that reflects the frequency or severity of word-finding problems. Scores are summed to yield a total score, with higher scores indicating greater perceived word-finding difficulty.
Administration time: ≈5 minutes
Measured: baseline, post- intervention (12 weeks)
Consortium to Establish a Registry for Alzheimer's Disease-CERAD constructional praxis (CP) and constructional praxis recall
Consortium to Establish a Registry for Alzheimer's Disease- CERAD constructional praxis (CP) and constructional praxis recall are subtests of the CERAD neuropsychological battery designed to assess visuospatial abilities and memory. The CP copying task involves the patient copying 4 geometric figures, while the CP recall task assesses the patient's ability to remember and reproduce these same figures after a delay. Performance is scored on an 11-point scale based on standardized criteria evaluating the accuracy, proportionality, spatial organization, and completeness of each drawing. Higher scores indicate better visuospatial performance.
Administration time: ≈5-10 minutes
Measured: baseline, post- intervention (12 weeks)
Geriatric Depression Scale - 15 Item Version
The Geriatric Depression Scale, 15-item version (GDS-15), is a widely used self-report screening instrument designed to assess depressive symptoms in older adults. It consists of 15 yes/no items that evaluate mood, motivation, energy, and cognitive-emotional symptoms associated with depression. Scoring is conducted by assigning 1 point to each response indicative of depressive symptomatology, resulting in a total score that ranges from 0 to 15.Higher scores indicate greater severity of depressive symptomatology.
Administration time: ≈5 minutes
Measured: baseline, post- intervention (12 weeks)
The Neuropsychiatric Inventory-12 Item Version
The Neuropsychiatric Inventory-12 (NPI-12) is a structured, informant-based assessment designed to measure the presence and severity of behavioral and psychological symptoms in individuals with neurocognitive disorders. The instrument evaluates 12 neuropsychiatric domains: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep disturbances, and appetite/eating changes. For each domain endorsed, the informant rates frequency (1-4) and severity (1-3). The domain score is calculated by multiplying frequency and severity, yielding values from 1 to 12 per domain. A separate caregiver distress rating (0-5) is also obtained for each domain to quantify the emotional impact on the caregiver. Total NPI-12 scores are derived by summing all domain scores, with higher scores reflecting greater neuropsychiatric symptom burden.
Administration time: ≈10 to 20 minutes
Measured: baseline, post- intervention (12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start1 Dec 2025
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Control Trial with Two Experimental Groups and one Control Group
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Patras
- Sponsor type
- University, hospital or other
- Collaborators
- University General Hospital of Patras, Andreas Mentzelopoulos Foundation
- Responsible party
- Principal investigator, Eftychia Nastou, University of Patras
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07334392
- Sponsor's protocol ID
- 17335/01-06-2025
- Acronym
- MExeProMCI
- Status last verified
- Dec 2025
- First submitted
- 21 Aug 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: happy to share the results after after processing all the data
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of an Innovative Therapeutic Exercise Program on Physical and Cognitive Function in Mild Cognitive Impairment Due to Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT07334392
- Acronym / sponsor ID
- MExeProMCI / 17335/01-06-2025
- Conditions
- Mild Cognitive Impairment, Walking, Balance, Cognition
- Keywords
- kinetic and kinematic, balance, global cognition, executive function, attention, mci, multicomponent program, exercise
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- University of PatrasUniversity, hospital or other
- Collaborators
- University General Hospital of Patras, Andreas Mentzelopoulos Foundation
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomised clinical trial is to investigate the effectiveness of an innovative therapeutic exercise program emphasizing in dual-task exercises in people with amnestic Mild Cognitive Impairment. The main questions it aims to answer are:
Does the innovative therapeutic exercise program improve gait and balance? Does the innovative therapeutic exercise program improve cognition?
Researchers will compare the innovative therapeutic exercise program emphasizing in dual-task exercises to a therapeutic exercise program without emphasizing in dual-task exercises and to a control group (given instruction about the benefits of exercise).
Participants will:
- Perform the exercise program twice a week for three months.
- Will be assessed before and after the intervention.
- Will record The Borg Scale of Perceived Exertion every second week to monitor and assess the progression of exercise intensity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Randomized Control Trial with Two Experimental Groups and one Control Group
| Arm | Type | Receives |
|---|---|---|
| Innovative therapeutic exercise program emphasizing in dual tasking | Experimental | Other: Innovative therapeutic exercise programParticipants will perform aerobic exercises, strengthening exercises and balance exercises combined with cognitive exercises at the same time for 60- 90 minutes/ twice a week/ three months. |
| Therapeutic exercise program | Active comparator | Other: Therapeutic exercise programParticipants will perform aerobic exercises, strengthening exercises and balance exercises for 60- 90 minutes/ twice a week/ three months. |
| Control group | Active comparator | Other: FlyerThe control group will be provided with educational material in the form of a flyer outlining the health benefits of exercise and general lifestyle recommendations. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- individuals > 50 years old
- people with confirmed cognitive impairment, as evidenced by values within normal limits on the Montreal Cognitive Assessment test (MOCA ) >20
- stable medication in the last month
- independent walking
Key exclusion criteria (6 listed)
- people with dementia
- people suffering from chronic mental illness (e.g. schizophrenia, bipolar disorder)
- people suffering from a neurological disorder or injuries (e.g. multiple sclerosis, Parkinson's, traumatic brain injury)
- people with clinical depression (as determined by the Neuropsychiatric Inventory (NPI) assessment and medical diagnosis)
- people who have had recent surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Innovative therapeutic exercise programAerobic, strengthening and balance exercises combined with cognitive training -name: Experimental group 1 (EXP1) | Other | Innovative therapeutic exercise program emphasizing in dual tasking |
| Therapeutic exercise programAerobic, strengthening and balance exercises without cognitive training- name: Experimental group 2 (EXP2) | Other | Therapeutic exercise program |
| FlyerThe control group will receive only educational material in the form of a flyer, outlining the importance and potential benefits of physical activity, along with general lifestyle recommendations, without participating in the structured exercise intervention- name: Control group (CG) | Other | Control group |
Primary outcome
Kinematic and kinetic gait assessment
Time frame: baseline, post- intervention (12 weeks)
Participants will be instructed to walk at their self-selected, comfortable walking pace. Gait performance will be assessed under four task conditions: single-task walking, dual-task walking, single-task obstacle crossing, and dual-task obstacle crossing. These conditions are designed to evaluate participants' walking ability and adaptability under both simple and cognitively demanding circumstances. Duration: ≈ 40 minutes
Functional Gait Assessment (FGA)
Time frame: baseline, post- intervention (12 weeks)
The Functional Gait Assessment is a clinical tool used to evaluate postural stability during various walking tasks. The assessment includes 10 standardized walking tasks, each addressing a distinct aspect of gait and balance. Performance on each task is rated on a 4-point ordinal scale (0-3), where higher scores indicate better functional performance. The total score ranges from 0 to 30, with a higher total score representing normal gait and balance, and a lower score indicating gait instability or impaired functional mobility. Test duration: ≈ 10-15 minutes
mini Balance Evaluation Systems Test (mini-BESTest)
Time frame: baseline, post- intervention (12 weeks)
The Mini-BESTest is a clinical balance assessment tool designed to evaluate dynamic balance control and identify the specific balance systems affected in individuals with balance disorders. It is a shortened version of the original Balance Evaluation Systems Test (BESTest). It comprises 14 items, each scored on a 3-point ordinal scale (0-2), with a maximum total score of 28 points. The assessment includes four subscales, each representing a specific component of balance control: Anticipatory Postural Adjustments - maximum score: 6 points Reactive Postural Control - maximum score: 6 points Sensory Orientation - maximum score: 6 points Dynamic Gait - maximum score: 10 points Higher scores indicate better balance performance, while lower scores reflect greater balance impairment. Test duration: ≈ 15minutes
Montreal Cognitive Assessment (MoCA)
Time frame: baseline, post- intervention (12 weeks)
The MoCA assesses global cognitive function across multiple domains. It includes 12 brief tasks, grouped into 7 cognitive domains: Total possible score: 30 points. Each task contributes a set number of points according to its complexity. If the individual has ≤ 12 years of education, 1 additional point is added to the total score to account for educational effects. Higher score indicates better global cognition while lower scores indicate impairment Administration time: ≈ 10-15 minutes
Cognitive Telephone Screening Instrument (COGTEL)
Time frame: baseline, post- intervention (12 weeks)
The test consists of six subtests, each targeting a specific cognitive domain: 1. Prospective Memory:(Score range: 0-2 points) 2. Verbal Short-Term Memory: (Score range: 0-8 points) 3. Verbal Long-Term Memory : (Score range: 0-8 points) 4. Working Memory (Backward Digit Span): (Score range: 0-12 points) 5. Verbal Fluency: (Score = number of correct words produced) 6. Inductive Reasoning: (Score range: 0-8 points) Each subtest yields an individual score, which are combined into a total composite score using a weighted formula reflecting the relative contribution of each domain to overall cognition: Total COGTEL score =(7.2 × Prospective Memory) + (1.0 × Verbal Short-Term Memory) + (0.9 × Verbal Long-Term Memory) + (0.8 × Working Memory) + (0.2 × Verbal Fluency) + (1.7 × Inductive Reasoning) Higher score indicates better cognitive performance while lower scores indicate impairment Administration time: ≈ 10-15 minutes
Stroop Test
Time frame: baseline, post- intervention (12 weeks)
The Stroop test is a sensitive index of executive function and attention. During the task, the participant is required to name the color of the ink in which a word is printed rather than read the word itself. Total number of correct responses within a set time limit (60 seconds), and number of errors (including self-corrections and uncorrected errors) are calculated. Higher scores indicate better executive control, while lower or negative scores suggest difficulty inhibiting automatic responses. Administration time: ≈5-10 minutes
12 secondary outcomes
Lipid profile
Time frame: baseline, post- intervention (12 weeks)
Hand grip strength test
Time frame: baseline, post- intervention (12 weeks)
30 Second Sit to Stand Test
Time frame: baseline, post- intervention (12 weeks)
Falls Efficacy Scale - International (FES-I)
Time frame: baseline, post- intervention (12 weeks)
6 Minute Walk Test (6MWT)
Time frame: baseline, post- intervention (12 weeks)
Timed Up and Go test (TUG)
Time frame: baseline, post- intervention (12 weeks)
Short Physical Performance Battery- (SPPB)
Time frame: baseline, post- intervention (12 weeks)
Exercise Adherence Rating Scale (EARS)
Time frame: end of 4 weeks of intervention, end of 8 weeks of intervention, end of intervention (12 weeks)
Word Finding Questionnaire - Brief Version (WoFi-Brief)
Time frame: baseline, post- intervention (12 weeks)
Consortium to Establish a Registry for Alzheimer's Disease-CERAD constructional praxis (CP) and constructional praxis recall
Time frame: baseline, post- intervention (12 weeks)
Geriatric Depression Scale - 15 Item Version
Time frame: baseline, post- intervention (12 weeks)
The Neuropsychiatric Inventory-12 Item Version
Time frame: baseline, post- intervention (12 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Individual participant dataSharing planned: Yes. happy to share the results after after processing all the data
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Active, not recruiting
EFFECTS OF AN OUTDOOR MAT PILATES PROGRAM ON NEUROPHYSIOLOGICAL INDICATORS OF ELDERLY INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT
Cognition Disorders
Recruiting
Combating Alzheimer's Through Sleep and Exercise
Dementia, Mild Cognitive Impairment (MCI)
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer's Disease
Recruiting
The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive Function for Persons at Risk of Dementia
Cognitive Enhancement, Subjective Cognitive Decline (SCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sofia Lampropoulou contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Innovative therapeutic exercise program, Therapeutic exercise program and Flyer in people with Mild Cognitive Impairment and Walking, run by University of Patras at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eftychia A Nastou (+30 6948694966, eutuxianastou@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Kinematic and kinetic gait assessment (time frame: baseline, post- intervention (12 weeks)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.